Idaho Veterans Research & Education Foundation

Nonprofit profile at a glance

EIN
453710305
IRS 990 coverage
2014–2024
Forms available
Form 990 2024
Location
Boise, ID, USA
Phone
2084221000
Rating
76
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Public Health Program (Includes General Health and Wellness Promotion Services)

Official website

Reported finances

Revenue
$1,139,352
Expenses
$1,176,168
Assets
$626,538
Liabilities
$56,830

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

9 people listed

Executive titles in this filing

  • MARGARET DOUCETTE (PRESIDENT)

Highest reported compensation

  • MARGARET K ALDAPE (EXECUTIVE DI): $85,606 total reported compensation
  • MICAH ROOS (CFO): $78,011 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

To advance the research and education mission of the department of veterans affairs and specifically the boise va medical center through the support of research and education related activities.

What it reported doing in 2024

Expenditures related to research and education. Research expenses associated with the following major grant projects: 1)nih (u of Idaho sub-award) - Idaho inbre program ivref doucette 2)nih (u of Idaho sub-award) - dhhs nih inbre4 ivref hobdey drp 3)nih r21 - role of mir-181a-5p in adenovirus 14p1 induced acute lung injury 4)nih ro3 - development of antibodies to specific cell surface markers to assess macrophage polarization during adenovirus 14 and 14p1 infection in the syrian hamster. 5) nih (u of pittsburgh sub-award) - macs/wihs ccs kunisaki 6)pcori (sibcr sub-award) - functional improvement in osa and copd with a telehealth lifestyle and exercise intervention (focused) 7)paratek pharmaceuticals - investigating the anti-inflammatory activities of omadacycline 8)alto pharmaceuticals - a randomized, double-blind, placebo-controlled study of alto-300 with an open-label extension in adults with major depressive disorder. 9)janssen research & development - multicohort study to customize ibrutinib treatment regimens for patients with previously untreated chronic lymphocytic leukemia 10)ferring pharmaceuticals - a phase 2, randomized, multi-center, open- label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade bacillus calmette-guerin (bcg) unresponsive non-muscle invasive bladder cancer (nmibc) 11)stability biologics - a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (camps) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers

Operating model

Revenue model
Earned-program. 73% of the money available for current operations came from fees and other program revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - A large share of available resources goes toward mission work and the filed numbers largely add up. Some filing-based governance responses are negative or unanswered and program spending has declined or grown slowly.

Rating breakdown

  • Financial Efficiency: 73
  • Transparency & Controls: 92
  • Accountability: 84
  • Sustainability: 28
  • Growth: 20

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 83%; rating input score 83
  • Program expense ratio: 80.3%; rating input score 80
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Yes; rating input score 100
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 5 of 8 controls in place; rating input score 62
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Fail
    • Document-retention policy: Fail
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: Fail
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Pass
    • Independent financial-statement audit: Pass

Sustainability

  • Operating margin: -3.2%; rating input score 27; 27th percentile among comparable filings
  • Total-asset coverage ratio: 0.53; rating input score 25; 25th percentile among comparable filings
  • Liabilities to assets ratio: 0.09; rating input score 44; 44th percentile among comparable filings
  • Officer compensation ratio: 13.9%; rating input score 25; 25th percentile among comparable filings

Growth

  • Program expense growth: -1.6% per year; rating input score 0; 13th percentile among comparable filings
  • Revenue growth: -2.5% per year; rating input score 0; 8th percentile among comparable filings
  • Asset growth: 0.2% per year; rating input score 100; 18th percentile among comparable filings

Details

  • Where the money goes: 83% of revenue deployed · 80.3% of spending went to programs
  • Governance: 7 of 7 board members independent · 5 of 8 filing controls reported
  • Programs: 1 filed program accomplishment · $945K in reported program spending
  • Leadership: top reported pay $86K · 9 people listed
  • Consistency: 29 of 29 current checks pass
  • Schedules: 5 filed schedules · includes major donors
  • Filing history: 11 filing years from 2014 to 2024
  • Contacts: How to reach this organization
  • Money network: 2 filed money-flow records
  • Related organizations: 1 filed related-organization link
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.
  • Staff and benefit plans: Retirement and health plans the organization files with the Department of Labor, and the people in them.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Review — Accountability: Governance controls: 3 of 8 not reported.
  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • High — Sustainability: Operating margin scored 27/100.
  • High — Sustainability: Total-asset coverage ratio scored 25/100.
  • High — Sustainability: Officer compensation ratio scored 25/100.
  • Moderate — Sustainability: Liabilities to assets ratio scored 44/100.